Microlin Bio Signs License Agreement With Université Laval

 

NEW YORK and QUEBEC CITY, Feb. 10, 2016 — Microlin Bio, Inc. (Microlin) (OTCBB:MICB) and Université Laval, today announced that they have entered into an exclusive license and research agreement through which Microlin and Université Laval will jointly develop microRNA-based treatments for Alzheimer’s Disease (AD). The program will be led by Université Laval Professor of Neuroscience Sébastien Hébert, a renowned expert in the field of microRNA research related to AD. Microlin will hold the exclusive worldwide license for the development and the commercialization of novel molecules and methods against certain microRNAs found to play a role in AD.

Subscribe to get the latest news